Nancy Newlin, MD | |
11325 N Crestview Drive, Fountain Hills, AZ 85268 | |
(480) 816-0601 | |
(480) 816-0259 |
Full Name | Nancy Newlin |
---|---|
Gender | Female |
Speciality | Radiology - Diagnostic Radiology |
Location | 11325 N Crestview Drive, Fountain Hills, Arizona |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1609097104 | NPI | - | NPPES |
1092491 | Medicaid | MI |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2085R0202X | Radiology - Diagnostic Radiology | 4301034709 (Michigan) | Secondary |
2085R0202X | Radiology - Diagnostic Radiology | 26018 (Arizona) | Primary |
Mailing Address | Practice Location Address |
---|---|
Nancy Newlin, MD Po Box 17138, Fountain Hills, AZ 85269 Ph: (480) 816-0601 | Nancy Newlin, MD 11325 N Crestview Drive, Fountain Hills, AZ 85268 Ph: (480) 816-0601 |
News Archive
Emerging evidence on the development, "prodromal" characteristics, and long-term course of schizophrenia provide reasons for optimism for developing new treatments and preventive approaches for this devastating disorder, according to the special March/April issue of Harvard Review of Psychiatry.
Changes in lifestyle could reduce the risk of developing Alzheimer's disease. That was the conclusion of a study conducted by researchers of Heidelberg University's Network Aging Research, who examined the data from two independent epidemiological studies. Carriers of the ApoE4 genetic risk factor for Alzheimer's may be able to reduce their increased risk of cognitive decline by reducing their cholesterol level, especially if they also suffer from cardiovascular disease.
Some countries in Africa "still rely on dichlorodiphenyltrichloroethane (DDT) for malaria vector control," therefore "[i]t is ... problematic that the U.N. Environment Programme (UNEP), without the consent of member states, and violating its own treaties, exerts relentless pressure to ban DDT globally," Richard Tren, director of Africa Fighting Malaria, and Richard Nchabi Kamwi, Nambia's minister of health and social services, write in a BMJ opinion piece.
Celgene Corporation and Abraxis BioScience Inc. today jointly announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Abraxis BioScience. Under the terms of the merger agreement, each share of Abraxis BioScience common stock will be converted into the right to receive an upfront payment of $58.00 in cash and 0.2617 shares of Celgene common stock.
› Verified 1 days ago